Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab
European Thyroid Journal · 2024
DOI: 10.1530/etj-23-0236 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Thyroid Journal, 2024. Verfasst von Ilaria Muller und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences and Community Health, University of Milan, Italy. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease, Multiple Sclerosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND Secondary thyroid autoimmunity, especially Graves’ disease (GD), frequently develops in patients with multiple sclerosis (MS) following alemtuzumab treatment (ALTZ; anti-CD52). Thyroid Eye Disease (TED) can also develop, and rituximab (RTX; anti-CD20) is a suitable treatment. METHODS Immunophenotyping of blood and thyroid-derived lymphocytes in a patient treated with both ALTZ and RTX. RESULTS A 37-year-old woman with MS developed steroid-resistant active moderate-to-severe TED three years after ALTZ, that successfully responded to a single 500 mg dose of i.v. RTX. Before RTX peripheral B-cells were low, and were totally depleted immediately after therapy. Follow-up analysis four years post-ALTZ and one year post-RTX, showed persistent depletion of B cells, and relative reduction of T regulatory cells in both peripheral blood and thyroid tissue obtained at thyroidectomy. CONCLUSIONS RTX therapy successfully inactivated TED in a patient with low B-cell count derived from previous ALTZ treatment. B-cell depletion in both thyroid and peripheral blood was still present one year after RTX, as a likely cumulative effect of both treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences and Community Health, University of Milan, Italy.
- Endocrinology Unit, Graves' Orbitopathy Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Ophthalmology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Specialistic Surgical Sciences, Otolaryngology and Head and Neck Surgery, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Endocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy.
- National Institute of Molecular Genetics (INGM) "Romeo and Enrica Invernizzi", Milan, Italy.
ORCID-Profile: Ilaria Muller, Sara Maioli, Mirco Armenti, Laura Porcaro, Lorenzo Pignataro, Caterina Mian, Jens Geginat
Zitieren
APA
Muller, I., Maioli, S., Armenti, M., Porcaro, L., Currò, N., Iofrida, E., Pignataro, L., Manso, J., Mian, C., Geginat, J., & Salvi, M. (2024). Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab. European Thyroid Journal. https://doi.org/10.1530/etj-23-0236
Vancouver
Muller I, Maioli S, Armenti M, Porcaro L, Currò N, Iofrida E, et al. Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab. European Thyroid Journal. 2024. doi:10.1530/etj-23-0236
BibTeX
@article{Muller2024,
author = {Muller, Ilaria and Maioli, Sara and Armenti, Mirco and Porcaro, Laura and Currò, Nicola and Iofrida, Elisabetta and Pignataro, Lorenzo and Manso, Jacopo and Mian, Caterina and Geginat, Jens and Salvi, Mario},
title = {Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab},
journal = {European Thyroid Journal},
year = {2024},
doi = {10.1530/etj-23-0236}
}
EUVIMED